Kapoor, RajatTimsina, Lava R.Gupta, NupurKaur, HarleenVidger, Arianna J.Pollander, Abby M.Jacobi, JudithKhare, SwapnilRahman, Omar2021-01-282021-01-282020-11-12Kapoor, R., Timsina, L. R., Gupta, N., Kaur, H., Vidger, A. J., Pollander, A. M., Jacobi, J., Khare, S., & Rahman, O. (2020). Maintaining Blood Glucose Levels in Range (70–150 mg/dL) is Difficult in COVID-19 Compared to Non-COVID-19 ICU Patients—A Retrospective Analysis. Journal of Clinical Medicine, 9(11), 3635. https://doi.org/10.3390/jcm91136352077-0383https://hdl.handle.net/1805/25045Beta cell dysfunction is suggested in patients with COVID-19 infections. Poor glycemic control in ICU is associated with poor patient outcomes. This is a single center, retrospective analysis of 562 patients in an intensive care unit from 1 March to 30 April 2020. We review the time in range (70–150 mg/dL) spent by critically ill COVID-19 patients and non-COVID-19 patients, along with the daily insulin use. Ninety-three in the COVID-19 cohort and 469 in the non-COVID-19 cohort were compared for percentage of blood glucose TIR (70–150 mg/dL) and average daily insulin use. The COVID-19 cohort spent significantly less TIR (70–150 mg/dL) compared to the non-COVID-19 cohort (44.4% vs. 68.5%). Daily average insulin use in the COVID-19 cohort was higher (8.37 units versus 6.17 units). ICU COVID-19 patients spent less time in range (70–150 mg/dL) and required higher daily insulin dose. A higher requirement for ventilator and days on ventilator was associated with a lower TIR. Mortality was lower for COVID-19 patients who achieved a higher TIR.en-USIUPUI Open Access PolicyAttribution 4.0 InternationalCOVID-19Intensive Care Units (ICU)Blood GlucoseInsulinRetrospective AnalysisArticle